Therapies and Biomarkers for Inflammatory Bowel Disease

Report Highlights

The market for inflammatory bowel disease therapeutics was valued at $4.8 billion in 2011 and should reach $5 billion in 2012. Total market value is expected to reach nearly $6.2 billion in 2017 after increasing at a five-year compound annual growth rate of 4.1%. 

Report Includes

• An overview of the global market for therapies and biomarkers for inflammatory bowel disease (IBD)
• Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017
• Discussion of the types of IBD, including Crohn's disease, ulcerative colitis, and other (ischemic, diversionary, Bechet's)
• Examination of the types of IBD diagnostics, such as stool cultures, blood tests, and colonoscopy, endoscopy and radiology; and therapies, such as clinical guidelines for managing the disease, drugs, and surgery
• A breakdown of research and development, the current drugs approved for treatment, and current clinical trials of drugs
• Industry structure, key competitive factors, and growth drivers and obstacles
• Comprehensive company profiles of key players.

SCOPE OF REPORT

The study scope of this report includes commercialized products used in the diagnosis and treatment of IBD, as well as novel products and technologies that may be commercially viable by 2017.  Important IBD disease mechanisms, technologies for biomarker discovery, industry structure, and key players and factors influencing demand for IBD therapeutics are discussed.  Suppliers of IBD diagnostic and therapeutic products are discussed, with the market for IBD therapeutics analyzed based on product types and regions.  In addition to an in-depth analysis of the intellectual property landscape for major industry players, this report highlights recent industrial shifts (e.g., strategic alliances, mergers and acquisitions, major venture capital deals) in the IBD diagnostic and therapeutic space.  Forecasted market growth from 2012 through 2017 is presented.

In addition to examining larger and more-established producers in IBD diagnostic and therapeutic product market segments, BCC Research profiled numerous smaller specialized market players in this report.  Market segmentation within the areas of therapeutic class and geographical areas are highlighted.  Each technology is analyzed by application type and in the context of relevant technological and regulatory forces to determine its current market status and forecasted growth through 2017.  Recent industrial alliances and acquisitions affecting producer market penetration and dominance are also discussed.

Topics that are specifically excludedfrom this study, as they are considered beyond the scope of this report, include a detailed market analysis for IBD diagnostic procedures (e.g., colonoscopy, endoscopy, radiology) and IBD classes with lower incidence and prevalence rates (e.g., ischemic, diversionary, Bechet’s).  A detailed market analysis for products used for the palliative care of IBD and non-laboratory diagnostics for IBD detection were also excluded from this study.

ANALYST CREDENTIALS

Dr. Willem Westra brings more than a decade of experience as an analyst in diverse areas of biomedical science, including basic research, intellectual property and investor relations, to BCC Research.  He is the author of several peer-reviewed scientific articles and book chapters, and he actively works with major domestic and international pharmaceutical and biotechnology companies to evaluate potential biomarkers for autoimmune diseases.  In addition to his pharmaceutical industry experience, Dr. Westra has served as an intellectual property/patent consultant, held visiting faculty positions in academia and has worked as a professional ski instructor.  Dr. Westra has earned both a B.S. in Pharmacological Chemistry and a Ph.D. in Biomedical Science from the University of California, San Diego.